Assessment of Left Ventricular Reverse Remodeling by Echocardiography After 90 Days of Sacubitril/Valsartan Therapy in Patients of Heart Failure with Reduced Ejection Fraction

Assessment of Left Ventricular Reverse Remodeling by Echocardiography After 90 Days of Sacubitril/Valsartan Therapy in Patients of Heart Failure with Reduced Ejection Fraction

Background: The present study aimed to assess the response of sacubitril/valsartan therapy on cardiac reverse remodeling (CRR) by standard and advanced echocardiographic parameters in patients of heart failure with reduced ejection fraction (HFrEF). Methods: One hundred and fifty patients ≥18 years...

Full description

Saved in:

Bibliographic Details
Main Authors:	Akshay Pawar, Rajesh Rajani, Deepak Sadashiv Phalgune
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2024-12-01
Series:	Journal of Indian College of Cardiology
Subjects:	cardiac reverse remodeling global longitudinal strain heart failure with reduced ejection fraction sacubitril/valsartan therapy
Online Access:	https://journals.lww.com/10.4103/jicc.jicc_7_24
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
by: Seonhwa Lee, et al.
Published: (2020-06-01)

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
by: Paolo Tolomeo, et al.
Published: (2022-06-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy
by: Neeraj Hiremath, et al.
Published: (2024-04-01)

Sacubitril/valsartan on right ventricular-pulmonary artery coupling and albumin-bilirubin score in heart failure in Chinese patients with reduced ejection fraction
by: Yanan Shi, et al.
Published: (2025-01-01)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
by: Charlotte Nordberg Backelin, et al.
Published: (2020-06-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits
by: Yu Chun, et al.
Published: (2021-09-01)

Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study
by: Yu Yan, et al.
Published: (2025-01-01)

The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis
by: Xinyue Yang, et al.
Published: (2024-12-01)

Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)
by: Koichi Yamamoto, et al.
Published: (2025-01-01)

Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration
by: Zhijie Liu, et al.
Published: (2022-06-01)

Beyond the Swell: Decoding the Enigma of Bilateral Hand Angioedema in Response to Sacubitril–valsartan Therapy
by: Samantha Aster Pinto, et al.
Published: (2024-10-01)

Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures
by: Stolarczyk Mariusz, et al.
Published: (2017-12-01)

Pharmacokinetics and Bioequivalence of Two Fixed-Dose Combination Tablets of Valsartan/Amlodipine (80/5 Mg) in Healthy Chinese Subjects
by: Tian M, et al.
Published: (2025-01-01)

Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan
by: Musko Monika, et al.
Published: (2014-12-01)

Efficacy of sacubitril/valsartan among patients with chronic heart failure with reduced ejection fraction
by: Madiha Butt, et al.
Published: (2024-09-01)

Short‐term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan
by: Simone Mazzetti, et al.
Published: (2020-06-01)

Analysis of Factors Related to Early Left Ventricular Dysfunction in Hypertensive Patients with Preserved Ejection Fraction Using Speckle Tracking Echocardiography: A Cross-Sectional Study in Vietnam
by: Hoang M. Tran, et al.
Published: (2025-01-01)

Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction
by: Anouk Achten, et al.
Published: (2025-04-01)

Outcomes of Worsened Left Ventricular Ejection Fraction After Transcatheter Aortic Valve Replacement
by: Hu Z, et al.
Published: (2025-01-01)

Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure
by: Philippine Kiès, et al.
Published: (2025-01-01)

Left ventricular remodeling and its association with mineral and bone disorder in kidney transplant recipients
by: Li Sun, et al.
Published: (2024-12-01)

Machine Learning for Predicting the Bz Magnetic Field Component From Upstream in Situ Observations of Solar Coronal Mass Ejections
by: M. A. Reiss, et al.
Published: (2021-12-01)

Circulating miRNA-486 as a novel diagnostic biomarker for right ventricular remodeling
by: Huiling Cai, et al.
Published: (2025-01-01)

IMPROVING EFFICIENCY OF THE JET PUMP AT LOW COEFFICIENTS OF EJECTION
by: A. G. Butenko, et al.
Published: (2015-06-01)

Characterization of heart failure patients with reverse left ventricular remodelling post‐angiotensin receptor blockers/neprilysin inhibitors therapy
by: Leonid Maizels, et al.
Published: (2022-06-01)

Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01)

Socioeconomic status and left ventricular ejection fraction decline in breast cancer survivors following receipt of doxorubicin (PREVENT WF-98213)
by: Arnethea L. Sutton, et al.
Published: (2025-02-01)

Left ventricular ejection time: its relation to left ventricular systolic function and functional capacity in cardiomyopathic patients
by: Eman S. El Shahawy, et al.
Published: (2024-04-01)

Predictive value of epicardial fat thickness for left ventricular reverse remodeling after radiofrequency ablation in atrial fibrillation patients with left ventricular hypertrophy
by: Ke Hu, et al.
Published: (2025-01-01)

Improving Predictions of High‐Latitude Coronal Mass Ejections Throughout the Heliosphere
by: C. Scolini, et al.
Published: (2020-03-01)

In Vitro Model of Vascular Remodeling Under Microfluidic Perfusion
by: Kotaro Nishikata, et al.
Published: (2024-12-01)

Solar Coronal Mass Ejection and Post–Coronal Mass Ejection Blob Formation in Two-fluid Simulations
by: J. C. Du, et al.
Published: (2025-01-01)

Clinical features and choice of the revascularization method in patients with stable coronary heart disease and preserved left ventricular ejection fraction
by: Yu.A. Borkhalenko, et al.
Published: (2017-06-01)

The Visual Complexity of Coronal Mass Ejections Follows the Solar Cycle
by: S. R. Jones, et al.
Published: (2020-10-01)

Hypermethylation of Hif3a and Ifltd1 is associated with atrial remodeling in pressure-overload murine model
by: Keiko Abe, et al.
Published: (2025-01-01)

Characteristics and Outcomes of Heart Failure Outpatients with Improvement in Ejection Fraction in Qatar
by: Rasha Kaddoura, et al.
Published: (2024-07-01)

Semi-Keplerian Magnetized Accretion-Ejection Structures
by: Seyedeh Zeynab Mousavi, et al.
Published: (2021-07-01)